Guselkumab's CD64 Binding Offers Targeted IL-23 Inhibition in PsAByPhilip J. Mease, MD,Kaitlyn Bader, Assistant Managing EditorJuly 10th 2026
Why Do Some Psoriasis Patients Respond Differently to Biologics? New Study Offers CluesByShannon Heaning, Content AssociateJuly 7th 2026
Smoking Associated with Increased Nail Psoriasis Severity, Case-Control Study FindsByMarie Bosslett, Assistant EditorJuly 7th 2026
First-in-Class Oral Piclidenoson Reaches Pivotal Phase 3 Enrollment Milestone in Plaque PsoriasisByShannon Heaning, Content AssociateJuly 6th 2026